Atea Pharmaceuticals AVIR

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.01 (-0.33%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Atea Pharmaceuticals (AVIR)
    Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.99

    • Market Cap

      $255.72 Million

    • Price-Earnings Ratio

      -1.50

    • Total Outstanding Shares

      84.46 Million Shares

    • Total Employees

      75

    • Dividend

      No dividend

    • IPO Date

      October 30, 2020

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      225 franklin street, Boston, MA, 02110

    • Homepage

      https://www.ateapharma.com

    Historical Stock Splits

    If you bought 11 shares of AVIR before February 14, 2018, you'd have 1 share today.
    Execution DateSplit Amount
    February 14, 20181-for-11 (Reverse Split)

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow$-79.13 Million
    Net Cash Flow, Continuing$-79.13 Million
    Net Cash Flow From Operating Activities$-135.50 Million
    Net Cash Flow From Financing Activities, Continuing$267,000
    Net Cash Flow From Investing Activities$56.10 Million
    Net Cash Flow From Investing Activities, Continuing$56.10 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Income Tax Expense/Benefit$925,000
    Net Income/Loss Available To Common Stockholders, Basic$-168.38 Million
    Research and Development$144.10 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Net Income/Loss Attributable To Parent$-168.38 Million
    Diluted Earnings Per Share$-2

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Comprehensive Income/Loss$26,000
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-168.36 Million
    Comprehensive Income/Loss$-168.36 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Equity$438.87 Million
    Accounts Payable$4.46 Million
    Current Assets$462.36 Million
    Liabilities$25.80 Million
    Noncurrent Liabilities$7.20 Million
    Assets$464.67 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AVIR from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.